BAKSHANDER KAUR: Open Payments
NPI 1477041192 · STOCKTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$853 in 30 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $336 · 2025 $853
Food & beverage: $853
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $293 |
| Axsome Therapeutics, Inc. | 4 | $178 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Neurocrine BioSciences, Inc. | 2 | $53 |
| Lundbeck LLC | 2 | $46 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Tris Pharma Inc | 1 | $17 |
Products named: VRAYLAR, Auvelity, REXULTI, TRINTELLIX, INGREZZA, INVEGA SUSTENNA, CAPLYTA, COBENFY.
Industry payments across CA — which companies pay providers there.
